Gyre Therapeutics (GYRE)
NASDAQ:GYRE
GYRE Stock Chart & Stats
$6.81
-$0.21(-2.15%)
At close: 4:00 PM EST
$6.81
-$0.21(-2.15%)
Day’s Range― - ―
52-Week Range$6.11 - $11.78
Previous CloseN/A
Volume104.17K
Average Volume (3M)102.52K
Market Cap
$650.16M
Enterprise Value$614.02M
Total Cash (Recent Filing)$52.42M
Total Debt (Recent Filing)$939.00K
Price to Earnings (P/E)125.5
Beta1.84
Next Earnings
May 08, 2026EPS Estimate
-0.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding91,314,010
10 Day Avg. Volume112,833
30 Day Avg. Volume102,519
Financial Highlights & Ratios
PEG Ratio-2.10
Price to Book (P/B)5.95
Price to Sales (P/S)5.41
P/FCF Ratio-3.50K
Enterprise Value/Market Cap0.94
Enterprise Value/Revenue5.27
Enterprise Value/Gross Profit5.52
Enterprise Value/Ebitda41.73
Forecast
1Y Price Target
$19.00Price Target Upside179.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.31
Revenue Forecast (FY)$148.00M
Bulls Say, Bears Say
Bulls Say
Acquisition Expands Technology And PipelineAcquisition of Cullgen adds a targeted protein degrader and degrader antibody conjugate platform, broadening the pipeline into cancer and pain with differentiated scientific approaches that can enhance long-term value.
Commercial Revenue Supporting R&DCurrent product revenue combined with China-based manufacturing provides a funding base to support ongoing clinical development and diversify growth drivers beyond single programs.
Regulatory Progress In ChinaChina's drug regulator indicating hydronidone meets priority review criteria and that existing Phase 3 data generally support a conditional NDA submission could accelerate approval timing and lower regulatory uncertainty.
Bears Say
Confirmatory Trial RequirementAgreement to conduct an additional confirmatory clinical trial to convert conditional approval into full approval creates extra clinical expense and regulatory risk that could delay full market access.
Earnings Shortfall ImpactReported earnings per share missing analyst and consensus expectations may weigh on investor sentiment and constrain near-term stock momentum.
Gyre Therapeutics News
GYRE FAQ
What was Gyre Therapeutics’s price range in the past 12 months?
Gyre Therapeutics lowest stock price was $6.11 and its highest was $11.78 in the past 12 months.
What is Gyre Therapeutics’s market cap?
Gyre Therapeutics’s market cap is $650.16M.
When is Gyre Therapeutics’s upcoming earnings report date?
Gyre Therapeutics’s upcoming earnings report date is May 08, 2026 which is in 32 days.
How were Gyre Therapeutics’s earnings last quarter?
Gyre Therapeutics released its earnings results on Mar 12, 2026. The company reported -$0.02 earnings per share for the quarter, missing the consensus estimate of $0.057 by -$0.077.
Is Gyre Therapeutics overvalued?
According to Wall Street analysts Gyre Therapeutics’s price is currently Undervalued.
Does Gyre Therapeutics pay dividends?
Gyre Therapeutics pays a Quarterly dividend of $3.6 which represents an annual dividend yield of N/A. See more information on Gyre Therapeutics dividends here
What is Gyre Therapeutics’s EPS estimate?
Gyre Therapeutics’s EPS estimate is -0.07.
How many shares outstanding does Gyre Therapeutics have?
Gyre Therapeutics has 91,314,010 shares outstanding.
What happened to Gyre Therapeutics’s price movement after its last earnings report?
Gyre Therapeutics reported an EPS of -$0.02 in its last earnings report, missing expectations of $0.057. Following the earnings report the stock price went down -6.303%.
Which hedge fund is a major shareholder of Gyre Therapeutics?
Currently, no hedge funds are holding shares in GYRE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Gyre Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-40.79%
12-Months-Change
Fundamentals
Return on Equity
5.46%
Trailing 12-Months
Asset Growth
32.48%
Trailing 12-Months
Company Description
Gyre Therapeutics
Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. It offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under phase 3 studies for dermatomyositis and systemic sclerosis-associated interstitial lung disease, pneumoconiosis, and diabetic kidney disease. The company is also involved the development of F351 (Hydronidone), a structural derivative of ETUARY (Pirfenidone), under Phase 3 studies for the treatment of chronic hepatitis B liver fibrosis; and under Phase 1 studies for liver fibrosis associated with nonalcoholic associated steatohepatitis. In addition, its development pipeline includes F573, under Phase 2 studies for the treatment of acute/acute-on-chronic liver failure; F528, under preclinical stage for the treatment of chronic obstructive pulmonary disease; and F230, under preclinical stage for the treatment of pulmonary arterial hypertension. The company was founded in 2002 and is headquartered in San Diego, California. Gyre Therapeutics, Inc. operates as a subsidiary of GNI USA, Inc.
GYRE Stock 12 Month Forecast
Average Price Target
$19.00
▲(179.00% Upside)
Technical Analysis
KalVista Pharmaceuticals
―
Terns Pharmaceuticals
―
Day One Biopharmaceuticals
―
Tyra Bioscience
―
MBX Biosciences, Inc.
―
Ownership Overview
3.87% Insiders
1.58% Mutual Funds
<0.01% Other Institutional Investors
92.84% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---